interferon alfacon-1 + interferon gamma-1b + ribavirin

A triple combination therapy comprising **interferon alfacon-1** (a recombinant consensus type I interferon-alpha), **interferon gamma-1b** (a recombinant type II interferon), and **ribavirin** (a synthetic nucleoside analogue antiviral). This regimen has been investigated for use in patients with chronic hepatitis C who have previously failed combination therapy with pegylated interferon and ribavirin[4]. Interferon alfacon-1 exerts its effect by modulating immune responses and inhibiting viral replication through induction of interferon-stimulated genes, while interferon gamma-1b activates macrophages and promotes cell-mediated immunity. Ribavirin acts synergistically by inhibiting the replication of RNA and DNA viruses; in combination with interferons, its antiviral efficacy is enhanced[4][1]. The combination's use is primarily experimental, with case reports and limited studies suggesting potential benefit in hepatitis C patients nonresponsive to standard therapy[4].

Brand names

Infergen (for interferon alfacon-1)

Other names

interferon alfacon-1interferon gamma-1bribavirin